Correction: Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin
Jing Qian, Wei Cheng, Shuangyan Li, Li Deng, Di Gao, Xue Zhang, Yunhui Zhang
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Treatments and Mutations · Computational Drug Discovery Methods · Magnolia and Illicium research
There was a mistake in Figures 2, 3, 6 as published. In Figures 2F,G, 3D, 6A,D, the compound name “Rhoifolin” was incorrectly spelled as “Phoifolin” in the bar graph for cell lines H358 and H1299. In Figure 2B, the legend label for the “48 h” time point was incorrectly written as “48 4”. In Figure 3D, the asterisks indicating statistical significance on the bar graph were omitted. The corrected Figures 2, 3, 6 appear below.
The original article has been updated.